valeant pharmaceuticals inte
(VRX:New York Consolidated)
Transactions by VALEANT PHARMACEUTICALS INTE (VRX) in the last 6 months
Valeant Pharmaceuticals International, Inc. (TSX:VRX) reached an agreement to acquire U.S. and Canadian business from Commonwealth Laboratories, Inc. on July 23, 2015. The deal provides for an up-front purchase price to be paid by Valeant on closing, with the opportunity for additional sales-based milestones payments. Commonwealth’s existing management team will remain in place and will continue to drive the strategic direction of the company. Commonwealth’s current ...
Valeant Pharmaceuticals International, Inc. (TSX:VRX) entered into a definitive agreement to acquire Amoun Pharmaceutical Company S.A.E. for $800 million on July 17, 2015. As part of consideration, some additional contingent payments will be made by Valeant. Valeant intends for Amoun to serve as a platform for further expansion in the broader Middle East and North Africa. The deal is subject to customary closing conditions and is expected to close in third quarter of ...
Capital International, Inc.
Valeant Pharmaceuticals International, Inc. (TSX:VRX) entered into a definitive agreement to acquire Unilens Vision Inc. (OTCPK:UVIC) for $22.4 million in cash on July 10, 2015. Under the terms, Valeant Pharmaceuticals is offering $12.75 in cash for each outstanding common stock and option of Unilens. The transaction will terminate if not completed by October 31, 2015. Unilens will be required to pay a termination fee of $0.7 million equivalent to 3.5% of the equity ...
Pershing Square Capital Management, L.P. through its fund Pershing Square Holdings, Ltd. (ENXTAM:PSH) acquired 4.9% stake in Valeant Pharmaceuticals International, Inc. (TSX:VRX) for $3.3 billion on March 9, 2015. Pershing acquired 16.5 million shares of Valeant. As on March 20, 2015, the transaction received early termination of antitrust approval. Tim Burt of StockWell Communications acted as public relations advisor in the deal. Davies Ward Phillips & Vineberg LLP ...
|Abbott Laboratories||$50.50 USD||-0.19|
|Astellas Pharma Inc||¥1,922 JPY||+0.50|
|Bristol-Myers Squibb Co||$65.34 USD||-0.30|
|Celgene Corp||$131.47 USD||+0.22|
|Eli Lilly & Co||$84.14 USD||-0.37|
|View Industry Companies|